Tragara Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical and commercial development of proprietary drugs for the treatment of various cancers. Tragara Pharmaceuticals is focusing its development efforts on three NCEs and 1 companion diagnostic: Capoxigem (apricoxib, TG01) for the treatment of solid tumors and inflammation-related disorders; TG02, a novel small molecule that blocks, within a narrow potency range, major signaling pathways involving JAK2, FLT3, ERK5 and key cell cycle and transcriptional regulatory cyclin-dependent kinases (CDKs), with excellent pharmacological and pharmaceutical properties, and the flexibility of oral administration. The kinase pathways modulated by TG02 drive disease progression and survival in hematologic malignancies and solid tumors; TG03, a combination product of Capoxigem and an EGFR-TKI; ProGEM, our proprietary diagnostic being developed as a companion to Capoxigem, designed to execute our personalized medicine strategy.